You searched for "prostate cancer"
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...
PET imaging of prostate-specific membrane antigen in prostate cancer
Molecular imaging utilising prostate-specific membrane antigen (PSMA) as a target has increasingly been mentioned at key conferences and meetings. PSMA is a membrane metalloenzyme that is overexpressed in prostate cancer, with the degree of expression appears to correlate with tumour...
Intermittent vs. continuous hormonal therapy for metastatic prostate cancer
Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...
The potential of statin use in castrate resistant prostate cancer treatment
One of the mechanisms by which prostate cancer achieves castrate resistance is through de novo intratumoral production of androgens. Reactivation of androgen receptors results in promotion of cell survival and proliferation pathways despite castrate serum testosterone levels. As androgen synthesis...Prostate cancer spit test could save the NHS £500 million a year
Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home. An innovative new study launched this week,...Black men are more at risk from prostate cancer, but we won’t let it stay that way – an update from Prostate Cancer Research
- CHARITY FOCUS - Focusing on all of disease characteristics, societal factors, and better communication gives us real potential to fix a disparity that has persisted for too long. When it comes to health inequity, the numbers are stark. Black...
Trade-offs between risks and benefits of localised prostate cancer treatments – the COMPARE study
We know little about the trade-offs men make when considering the oncological and functional outcomes of individual treatment options for localised prostate cancer, and decisions are often influenced by physician opinion. The likely compromised functional results are viewed as a...
Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study
This study examined a cohort of non-statin using patients who participated in the REDUCE study. The REDUCE study included men who had an elevated prostate specific antigen (PSA) and a negative baseline prostate biopsy who then underwent year two and...
